ArticlePloS one2025
Antibacterial and antiviral potential of harmalacidine hydrochloride, a β-carboline alkaloid, against respiratory tract pathogens: Staphylococcus aureus and H1N1 influenza virus.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory infections remain a leading cause of morbidity and mortality, necessitating new therapeutic strategies. This study evaluated the antiviral and antibacterial activities of harmine, harmaline, and harmalacidine hydrochloride against H1N1 influenza virus and Staphylococcus aureus, key respiratory pathogens. The in vitro antiviral activity of the tested compounds against the H1N1 virus was evaluated using a plaque assay. Harmalacidine hydrochloride demonstrated notable activity, with an IC50 of 68.2 ± 0.8 µg/mL, while harmine and harmaline showed no significant effects at non-cytotoxic concentrations. The potential antibacterial action of the tested compounds was initially investigated by agar well diffusion method, which revealed clear zones of inhibition around the wells. Subsequently, their minimum inhibitory concentrations (MICs) were recorded using the broth microdilution method. Harmalacidine hydrochloride exhibited the highest antibacterial action with MICs from 16 to 128 µg/mL. Based on these findings, further investigations were conducted to assess the effect of harmalacidine hydrochloride on membrane integrity and permeability, cellular morphology, and biofilm formation. A noticeable reduction (p < 0.05) in the membrane integrity and a distinct escalation (p < 0.05) in the permeability were noticed in 46.15% and 53.85% of the tested isolates, respectively. Moreover, scanning electron microscopy revealed pronounced distortion in cellular morphology following harmalacidine hydrochloride treatment. The compound also exhibited antibiofilm activity, as demonstrated by the crystal violet assay, alongside a downregulation of biofilm-associated gene expression. Molecular docking revealed that harmalacidinium ion binds strongly to the Accessory Gene Regulator A (AgrA) of S. aureus, suggesting antibacterial activity through inhibition of quorum sensing-mediated virulence. It also showed high affinity for H1N1 neuraminidase and polymerase basic protein 2 (PB2), indicating potential antiviral activity. However, experimental enzyme assays and in vivo studies are required to confirm the proposed antiviral and antibacterial mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.